B J Ring

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi request reprint The effect of incubation conditions on the enzyme kinetics of udp-glucuronosyltransferases
    Matthew G Soars
    Department of Drug Disposition, Lilly Research Laboratories, Drop Code 0710, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Drug Metab Dispos 31:762-7. 2003
  2. ncbi request reprint Present and future in vitro approaches for drug metabolism
    S Ekins
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Drop Code 0730, Indianapolis, IN 46285, USA
    J Pharmacol Toxicol Methods 44:313-24. 2000
  3. ncbi request reprint Identification of the human cytochromes p450 responsible for in vitro formation of R- and S-norfluoxetine
    B J Ring
    Department of Drug Disposition, Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, Indiana, USA
    J Pharmacol Exp Ther 297:1044-50. 2001
  4. ncbi request reprint Flavin-containing monooxygenase-mediated N-oxidation of the M(1)-muscarinic agonist xanomeline
    B J Ring
    Eli Lilly and Co, Indianapolis, Indiana 46285, USA
    Drug Metab Dispos 27:1099-103. 1999
  5. ncbi request reprint The interactions of a selective protein kinase C beta inhibitor with the human cytochromes P450
    Barbara J Ring
    Department of Drug Disposition, Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, Indiana, USA
    Drug Metab Dispos 30:957-61. 2002
  6. ncbi request reprint Identification of the human cytochromes P450 responsible for atomoxetine metabolism
    Barbara J Ring
    Department of Drug Disposition, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Drug Metab Dispos 30:319-23. 2002
  7. ncbi request reprint Three- and four-dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors
    S Ekins
    Department of Drug Disposition, Lilly Research Laboratories, Eli Lilly and Co, Lilly Corporate Center, Indianapolis, Indiana, USA
    Drug Metab Dispos 28:994-1002. 2000
  8. ncbi request reprint Alterations of the catalytic activities of drug-metabolizing enzymes in cultures of human liver slices
    M VandenBranden
    Department of Drug Disposition, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Drug Metab Dispos 26:1063-8. 1998
  9. ncbi request reprint Examination of purported probes of human CYP2B6
    S Ekins
    Department of Drug Disposition, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Pharmacogenetics 7:165-79. 1997
  10. ncbi request reprint A novel testosterone 6 beta-hydroxylase activity assay for the study of CYP3A-mediated metabolism, inhibition, and induction in vitro
    J L Fayer
    Lilly Research Laboratories, Department of Drug Disposition, Eli Lilly and Company, Lilly Corporate Center, DC0730, Indianapolis, IN 46285, USA
    J Pharmacol Toxicol Methods 46:117-23. 2001

Detail Information

Publications17

  1. ncbi request reprint The effect of incubation conditions on the enzyme kinetics of udp-glucuronosyltransferases
    Matthew G Soars
    Department of Drug Disposition, Lilly Research Laboratories, Drop Code 0710, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Drug Metab Dispos 31:762-7. 2003
    ..In conclusion, the Hill and/or Michaelis-Menten equations should be used to fit kinetic data to obtain an accurate assessment of in vitro glucuronidation...
  2. ncbi request reprint Present and future in vitro approaches for drug metabolism
    S Ekins
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Drop Code 0730, Indianapolis, IN 46285, USA
    J Pharmacol Toxicol Methods 44:313-24. 2000
    ..This review will focus on and assess the nature of present in vitro metabolism approaches and indicate how they are likely to develop in the future...
  3. ncbi request reprint Identification of the human cytochromes p450 responsible for in vitro formation of R- and S-norfluoxetine
    B J Ring
    Department of Drug Disposition, Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, Indiana, USA
    J Pharmacol Exp Ther 297:1044-50. 2001
    ....
  4. ncbi request reprint Flavin-containing monooxygenase-mediated N-oxidation of the M(1)-muscarinic agonist xanomeline
    B J Ring
    Eli Lilly and Co, Indianapolis, Indiana 46285, USA
    Drug Metab Dispos 27:1099-103. 1999
    ..c. dosing as compared with oral dosing may be due to differences in the affinity of various FMO family members for xanomeline or to differences in exposure to xanomeline that these enzymes receive under different dosing regimens...
  5. ncbi request reprint The interactions of a selective protein kinase C beta inhibitor with the human cytochromes P450
    Barbara J Ring
    Department of Drug Disposition, Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, Indiana, USA
    Drug Metab Dispos 30:957-61. 2002
    ..Therefore, alterations in the activity of this enzyme have the potential to affect LY333531 clearance. In addition, LY333531 and its metabolite are predicted to be potential inhibitors of CYP2D6-mediated reactions in vivo...
  6. ncbi request reprint Identification of the human cytochromes P450 responsible for atomoxetine metabolism
    Barbara J Ring
    Department of Drug Disposition, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Drug Metab Dispos 30:319-23. 2002
    ..Therefore, coadministration of P450 inhibitors to poor metabolizers of CYP2D6 substrates would not be predicted to decrease the clearance of atomoxetine in these individuals...
  7. ncbi request reprint Three- and four-dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors
    S Ekins
    Department of Drug Disposition, Lilly Research Laboratories, Eli Lilly and Co, Lilly Corporate Center, Indianapolis, Indiana, USA
    Drug Metab Dispos 28:994-1002. 2000
    ..These 3D- and 4D-QSAR models of CYP inhibition will aid in future prediction of drug-drug interactions...
  8. ncbi request reprint Alterations of the catalytic activities of drug-metabolizing enzymes in cultures of human liver slices
    M VandenBranden
    Department of Drug Disposition, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Drug Metab Dispos 26:1063-8. 1998
    ..Therefore, the development of culture methods for human liver slices that can improve the preservation of the drug-metabolizing capabilities may be required...
  9. ncbi request reprint Examination of purported probes of human CYP2B6
    S Ekins
    Department of Drug Disposition, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Pharmacogenetics 7:165-79. 1997
    ..Furthermore, the specificity of both antibody and chemical inhibitor (ORP) probes previously suggested to be specific for CYP2B6 is also questioned...
  10. ncbi request reprint A novel testosterone 6 beta-hydroxylase activity assay for the study of CYP3A-mediated metabolism, inhibition, and induction in vitro
    J L Fayer
    Lilly Research Laboratories, Department of Drug Disposition, Eli Lilly and Company, Lilly Corporate Center, DC0730, Indianapolis, IN 46285, USA
    J Pharmacol Toxicol Methods 46:117-23. 2001
    ..This assay has been determined to be useful for the study of both inhibition- and induction-related drug-drug interactions in vitro and involves simple incubation and sample handling procedures...
  11. ncbi request reprint The use of in vitro metabolism techniques in the planning and interpretation of drug safety studies
    S A Wrighton
    Department of Drug Metabolism and Disposition, Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    Toxicol Pathol 23:199-208. 1995
    ..An example of how such information is generated and interpreted is presented...
  12. ncbi request reprint Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450
    Jessica L Fayer Rehmel
    Department of Drug Disposition, Eli Lilly and Company, Lilly Corporate Center DC0714, Indianapolis, IN 46285, USA
    Drug Metab Dispos 34:600-7. 2006
    ..These K(i) values exceed circulating concentrations in humans by 3.8- to 43-fold. Therefore, neither R-95913 nor R-138727 is expected to substantially inhibit the P450-mediated metabolism of coadministered drugs...
  13. ncbi request reprint Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7
    J Andrew Williams
    Department of Drug Disposition, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Drug Metab Dispos 30:883-91. 2002
    ..These results demonstrate an equal or reduced metabolic capability for CYP3A5 compared with CYP3A4 and a significantly lower capability for CYP3A7...
  14. ncbi request reprint Differential modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1)-catalyzed estradiol-3-glucuronidation by the addition of UGT1A1 substrates and other compounds to human liver microsomes
    J Andrew Williams
    Department of Drug Disposition, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Drug Metab Dispos 30:1266-73. 2002
    ..This study demonstrates that the interactions of substrates and inhibitors at the active site of UGT1A1 are complex, yielding both activation and competitive inhibition kinetics...
  15. ncbi request reprint Effect of tadalafil on cytochrome P450 3A4-mediated clearance: studies in vitro and in vivo
    Barbara J Ring
    Eli Lilly and Company, Indianapolis, IN 46285, USA
    Clin Pharmacol Ther 77:63-75. 2005
    ..Tadalafil was examined in vitro and in vivo for its ability to affect human cytochrome P450 (CYP) 3A-mediated metabolism...
  16. ncbi request reprint Clinical pharmacokinetics of atomoxetine
    John Michael Sauer
    Elan Pharmaceuticals, Inc, South San Francisco, California, USA
    Clin Pharmacokinet 44:571-90. 2005
    ..In extensive metabolisers, potent and selective CYP2D6 inhibitors reduce atomoxetine clearance; however, administration of CYP inhibitors to poor metabolisers has no effect on the steady-state plasma concentrations of atomoxetine...
  17. ncbi request reprint Predictions of the in vivo clearance of drugs from rate of loss using human liver microsomes for phase I and phase II biotransformations
    Michael A Mohutsky
    Department of Drug Disposition, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Pharm Res 23:654-62. 2006
    ....